Paper Details

  1. Home
  2. Paper Details

Plasma concentrations of high-dose olanzapine in a double-blind crossover study.

Author: ConleyRobert R, KellyDeanna L, RichardsonCharles M, YuYang

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, N.I.H., ExtramuralResearch funding provided by the NIH to external research institutions and researchers.

Overview

This study examined the relationship of high-dose olanzapine plasma concentrations to symptoms, adverse effects, smoking, and gender in patients with treatment-resistant schizophrenia. Women had significantly higher olanzapine levels than men. Cigarette intake was negatively correlated with olanzapine levels, and higher levels were associated with constipation and anticholinergic effects.
Paper Details　
Original Abstract of the Article :
Olanzapine is structurally similar to clozapine but has not been shown at routine doses to share the superiority of clozapine to traditional antipsychotics in treatment-resistant patients. Olanzapine, however, has been increasingly used in higher doses as clinicians attempt to find a more tolerable ...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1002/hup.781

データ提供：米国国立医学図書館（NLM）

High-Dose Olanzapine: Exploring the Landscape of Antipsychotic Therapy

Olanzapine, an antipsychotic medication, is often used to treat schizophrenia and other psychotic disorders. This study investigates the relationship between plasma concentrations of high-dose olanzapine and various clinical factors, including symptoms, adverse effects, smoking, and gender. The researchers conducted a double-blind crossover study involving 13 patients, comparing high-dose olanzapine (50 mg/day) to clozapine (450 mg/day). Their findings reveal that women tend to have significantly higher plasma olanzapine levels than men, and that cigarette intake is negatively correlated with olanzapine levels. The study also identifies a potential link between higher olanzapine concentrations and certain side effects, such as constipation.

Navigating the Terrain of Antipsychotic Therapy: Gender and Smoking Factors

This study sheds light on the potential influence of gender and smoking on olanzapine pharmacokinetics. The finding that women tend to have higher olanzapine levels than men, and that cigarette smoking can influence olanzapine levels, underscores the importance of considering these factors in individualizing antipsychotic treatment. This research is like a map guiding us through the complex terrain of antipsychotic therapy, helping us understand the various factors that can influence drug efficacy and safety.

Understanding Olanzapine: A Journey Through the Desert of Antipsychotic Therapy

This study provides valuable insights into the pharmacokinetics of olanzapine, particularly at high doses. It highlights the potential influence of gender and smoking on olanzapine levels and the association between higher concentrations and certain side effects. This research is like a camel caravan, traversing the vast desert of antipsychotic therapy, providing valuable knowledge and guidance for clinicians and patients.

Dr.Camel's Conclusion

This study offers a deeper understanding of the factors influencing plasma concentrations of high-dose olanzapine, highlighting the importance of considering gender, smoking, and potential side effects in individualizing antipsychotic treatment. It's like a compass, guiding us through the complexities of antipsychotic therapy, ensuring a safe and effective journey for patients.

Date :
  1. Date Completed 2006-12-22
  2. Date Revised 2022-04-04
Further Info :

Pubmed ID

16850522

DOI: Digital Object Identifier

10.1002/hup.781

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.